Development of the UroMark assay. A non-invasive test for the detection of bladder cancer in urinary sediment cells

UroMark 检测的开发。

• 批准号: MR/M025411/1
• 负责人: John Kelly
• 金额: $ 181.9万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FM025411%2F1
• 关键词: Development; UroMark; assay.; non; invasive

Investigation for bladder cancer in patients with blood in their urine (haematuria) is important and incurs a cost to UK healthcare estimated at £55.39 million per year ranking bladder as one of the most expensive cancers to manage. Although haematuria is a sign of bladder cancer only 10% of patients with haematuria will be found to have cancer. In the majority of instances a non cancer cause and frequently no cause is found. The assessment of haematuria involves passing an instrument along the urethra, or water pipe, to view the lining of the bladder wall. The assessment known as cystoscopy is uncomfortable, carries a low but significant risk of infection and requires referral from a GP to hospital. We have developed a test which uses cutting edge technology known as highly multiplexed targeted sequencing to detect cancer specific changes known as epigenetic alterations in cells which can be collected from urine. A urine sample for testing can be provided at home and sent to our lab using the postal system. The test, UroMark, utilises a platform known as RainDrop BS-Seq to analyse a panel of 150 epigenetic alterations which accurately discriminate between bladder cancer and normal. In proof of concept studies the test performs with high sensitivity and specificity for the detection of bladder cancer. The incorporation of a highly sensitive and specific assay will revolutionise bladder cancer pathways, have a profound impact on the requirement for cystoscopy and on patient wellbeing and, reduce the healthcare costs associated with investigation of haematuria and surveillance for disease recurrence.

对尿血（血尿）患者的膀胱癌进行调查很重要，每年给英国医疗保健带来的成本估计为5539万英镑，膀胱是管理成本最高的癌症之一。虽然血尿是膀胱癌的征兆，但只有10%的血尿患者会被发现患有癌症。在大多数情况下，一个非癌症的原因，往往没有找到原因。血尿的评估涉及通过一个仪器沿着尿道，或水管，以查看膀胱壁的衬里。被称为膀胱镜检查的评估是不舒服的，感染的风险很低但很大，需要从全科医生转诊到医院。我们开发了一种测试，该测试使用称为高度多重靶向测序的尖端技术来检测可从尿液中收集的细胞中称为表观遗传改变的癌症特异性变化。可以在家里提供尿液样本进行测试，并通过邮政系统发送到我们的实验室。这项名为UroMark的测试利用一个名为RainDrop BS-Seq的平台来分析一组150个表观遗传学改变，这些改变可以准确区分膀胱癌和正常人。在概念验证研究中，该测试对膀胱癌的检测具有高灵敏度和特异性。高灵敏度和特异性测定的结合将彻底改变膀胱癌途径，对膀胱镜检查的要求和患者健康产生深远影响，并降低与血尿调查和疾病复发监测相关的医疗保健成本。

项目成果

Quantification of tumour evolution and heterogeneity via Bayesian epiallele detection

通过贝叶斯表观等位基因检测量化肿瘤进化和异质性

• DOI: 10.48550/arxiv.1702.00633
• 发表时间: 2017
• 作者: Barrett J

UroMark-a urinary biomarker assay for the detection of bladder cancer.

乌马克-A尿生物标志物测定用于检测膀胱癌。

• DOI: 10.1186/s13148-016-0303-5
• 发表时间: 2017
• 期刊: Clinical epigenetics
• 影响因子: 5.7
• 作者: Feber A;Dhami P;Dong L;de Winter P;Tan WS;Martínez-Fernández M;Paul DS;Hynes-Allen A;Rezaee S;Gurung P;Rodney S;Mehmood A;Villacampa F;de la Rosa F;Jameson C;Cheng KK;Zeegers MP;Bryan RT;James ND;Paramio JM;Freeman A;Beck S;Kelly JD
• 通讯作者: Kelly JD

Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.

• DOI: 10.1038/s41467-022-33544-x
• 发表时间: 2022-10-07
• 期刊: Nature communications
• 影响因子: 16.6

CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma.

• DOI: 10.1158/0008-5472.can-15-3134
• 发表时间: 2016-08-15
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Feber A;Worth DC;Chakravarthy A;de Winter P;Shah K;Arya M;Saqib M;Nigam R;Malone PR;Tan WS;Rodney S;Freeman A;Jameson C;Wilson GA;Powles T;Beck S;Fenton T;Sharp TV;Muneer A;Kelly JD
• 通讯作者: Kelly JD

Author Correction: Pan-cancer deconvolution of tumour composition using DNA methylation.

• DOI: 10.1038/s41467-018-07155-4
• 发表时间: 2018-11-02
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Chakravarthy A;Furness A;Joshi K;Ghorani E;Ford K;Ward MJ;King EV;Lechner M;Marafioti T;Quezada SA;Thomas GJ;Feber A;Fenton TR
• 通讯作者: Fenton TR